Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Loading...

References

  1. Thibaud Damy. Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.. European journal of heart failure, 2025
  2. Michelle M Kittleson. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.. Journal of the American College of Cardiology, 2025
  3. Adam Ioannou. Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy.. JAMA cardiology, 2024
  4. Michelle M Kittleson. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.. Journal of the American College of Cardiology, 2023
  5. Paul A Heidenreich. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. Journal of the American College of Cardiology, 2022
  6. P. García-Pavía. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021
  7. J. Gillmore. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018
  8. M. Grogan. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.. Journal of the American College of Cardiology, 2016